- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01014962
A Study of the Effects of Increasing Doses of a Drug for the Treatment of Nail Fungus
A Randomized, Double-Blind, Multiple-Dose, Placebo-Controlled Tolerability And Pharmacokinetic Study Of Escalating Doses Of Albaconazole In Healthy Subjects
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Wisconsin
-
West Bend, Wisconsin, United States, 53095
- Spaulding Clinical Research, LLC
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female subjects age 18 to 45
- A body mass index (BMI) between 18.5 and 30 kg/m2.
- Good physical and mental health.
- Vital signs .within the acceptable range.
- Electrocardiogram (12-lead) after at least 5 minutes in supine position considered as normal or with findings considered as not clinically significant by the investigator. .
- Non-smoker for at least 6 months before screening.
- Subject has screening laboratory parameters within the normal ranges unless considered to be not clinically relevant by the principal investigator. .
Subject is able to review and understand an informed consent, and must sign the independent ethics committee (IEC)/IRB approved informed consent form before any trial-related procedures are performed.
- Sexually active females of childbearing potential must have a negative serum pregnancy test result at screening. These subjects must use a medically acceptable method of contraception while receiving protocol-assigned product, and are expected to continue to use this method of contraception for up to 90 days following the last dose of the study medication. A woman of childbearing potential is defined as one who is biologically capable of becoming pregnant; including perimenopausal women who are less than 2 years from their last menses.
Women who are not currently sexually active or lactating must agree to use 2 forms of nonhormonal contraception, should they become sexually active while participating in the study, and for 90 days following the end of participation in the study. Male subjects and/or their partners must use a medically acceptable form of contraception while receiving protocol-assigned product, and up to 90 days following the last dose of the study medication.
- Subject is willing and able to take the assigned clinical trial medication as directed, comply with clinical trial instructions, and commit to all study visits.
Exclusion Criteria:
- History of intolerance to any of the ingredients in the study medications, or other related drugs, or history of relevant/clinically significant allergic reactions of any origin.
- Any disease or physical condition that, in the opinion of the investigator, could impact the PK/pharmacodynamics of the drug or could potentially compromise the safety of the subject.
- Subject has previously participated in a clinical study of albaconazole.
- History of drug, prescription medicine, or alcohol abuse within the past 2 years.
- Positive drug screen.
- History of psychological or other emotional problems that are likely to invalidate informed consent, or could limit the ability of the subject to comply with the protocol requirements.
- Any drug treatment taken within 14 days before the first drug intake or within 5 half-lives whichever is longer.
- Participation in another clinical trial, blood donation, or significant blood loss less than 30 days before the first intake of study drug.
- Unsuitable veins for repeated venipuncture.
- Subject has any known liver disease or liver toxicity with other drugs.
- Subject has a predose ECG before dosing with a QTcB or QTcF interval >450 msec, or abnormal morphology of the ECG, or clinically serious arrhythmia.
- Subjects who are pregnant, breast-feeding, women of childbearing potential not using adequate contraceptives or planning to conceive, or male subjects who plan to father a child as described in the informed consent.
- Positive for hepatitis B (HBsAg) or hepatitis C (Ab HCV) or HIV or AIDS.
- Consumption of any excluded drugs or foodstuff within 72 hours before dosing.
- Subjects who are employees of a clinical research organization involved in the study, or Stiefel, or an immediate family member.
- Subjects who have a member of the same household in this study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Albaconazole 400 mg cohort 1
Albaconazole 400 mg
|
Albaconozole 400 mg oral once daily for 5 days
Albaconozole 400 mg every 12 hours for 5 days
Albaconozole 400 mg oral every 8 hours for 5 days
|
Placebo Comparator: Placebo cohort 1
Placebo once daily
|
Placebo oral once daily for 5 days
Placebo oral every 12 hours for 5 days
Placebo oral every 8 hours for 5 days
|
Experimental: Albaconozole 400 mg cohort 2
Albaconozole 400 mg every 12 hours
|
Albaconozole 400 mg oral once daily for 5 days
Albaconozole 400 mg every 12 hours for 5 days
Albaconozole 400 mg oral every 8 hours for 5 days
|
Placebo Comparator: Placebo cohort 2
Placebo every 12 hours
|
Placebo oral once daily for 5 days
Placebo oral every 12 hours for 5 days
Placebo oral every 8 hours for 5 days
|
Experimental: Albaconozole 400 mg cohort 3
Albaconozole 400 mg every 8 hours
|
Albaconozole 400 mg oral once daily for 5 days
Albaconozole 400 mg every 12 hours for 5 days
Albaconozole 400 mg oral every 8 hours for 5 days
|
Placebo Comparator: Placebo cohort 3
Placebo every 8 hours
|
Placebo oral once daily for 5 days
Placebo oral every 12 hours for 5 days
Placebo oral every 8 hours for 5 days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Plasma concentrations of albaconazole in subjects
Time Frame: During 5 days of dosing and 15 days follow-up
|
During 5 days of dosing and 15 days follow-up
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Electrocardiogram (ECG) QTc values
Time Frame: During 5 days of dosing and 15 days follow-up
|
During 5 days of dosing and 15 days follow-up
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 114555
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Onychomycosis
-
Vésale HospitalJanssen-Cilag Ltd.CompletedPrevalence of Onychomycosis | Diabetic Neuropathic Patients | Diagnostic of Onychomycosis | Patients Clinically Suspected of Onychomycosis | Reliability of the Diagnosis of OnychomycosisBelgium
-
University of Alabama at BirminghamDUSA Pharmaceuticals, Inc.CompletedToenail Onychomycosis | Distal and Lateral Subungual Toenail OnychomycosisUnited States
-
DeviceFarm, Inc.Symbio, LLC; Center for Dermatology Clinical Research, Inc.CompletedOnychomycosis Due to Trichophyton Rubrum | Onychomycosis Due to Trichophyton MentagrophytesUnited States
-
Janssen Korea, Ltd., KoreaCompleted
-
Cairo UniversityRecruiting
-
Mediprobe Research Inc.Emblation LimitedRecruiting
-
Oystershell NVCompletedOnychomycosis of ToenailTunisia
-
Erchonia CorporationWithdrawnOnychomycosis of ToenailUnited States
-
William N HandelmanUnknown
-
DeviceFarm, Inc.CompletedOnychomycosis | Onychomycosis of ToenailUnited States